Showing 1 to 1 of 1 results
cnbc.com
🌐 85% Global Worthiness
FDA Approves Zepbound for Obstructive Sleep Apnea
The FDA approved Eli Lilly's Zepbound for treating obstructive sleep apnea (OSA), expanding its use beyond obesity; clinical trials showed 43-51.5% disease resolution in patients compared to 13.6-14.9% with placebo, potentially impacting 80 million Americans with OSA.
FDA Approves Zepbound for Obstructive Sleep Apnea
The FDA approved Eli Lilly's Zepbound for treating obstructive sleep apnea (OSA), expanding its use beyond obesity; clinical trials showed 43-51.5% disease resolution in patients compared to 13.6-14.9% with placebo, potentially impacting 80 million Americans with OSA.
Progress
56% Bias Score
Good Health and Well-being
Showing 1 to 1 of 1 results